Monographie - Dexmedetomidine

Utolsó frissítés :
14/12/2024

Dexmedetomidine

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Avemedit	Mexikó
Danmidrat	Mexikó
Demesynt	Mexikó
Dexdine	India
Dexdor	Belgium, Franciaország, Izland, Norvégia, Románia, Spanyolország
Dexem	India
Dexmedetomidina	Chile, Colombia
Dexmetin	Argentína, Chile
Dexodine	Chile, Peru
Dextocris	Chile
Dextomid	India
Drimitec	Mexikó
Eusedex	Chile, Peru
Frelig	Mexikó
Kmetodin	Ecuador
Krunamina	Mexikó
Precedex	Amerikai Egyesült Államok, Argentína, Chile, Colombia, Ecuador, Egyesült Arab Emírségek, India, Kanada, Malaysia, Mexikó, Peru, Szaúd-Arábiában, új-Zéland, Venezuela
Preser	Chile
Priaxim	Ecuador
Valertropina	Argentína
Xamdex	India

Irodalom : Dexmedetomidine

	Type	publikáció
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
3152	Napló	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3299	Napló	Anderson C.R, Mackay M.W, Holley M, Kay B.A Stability of dexmedetomidine 4 µg/mL in polypropylene syringes. Am J Health-Syst Pharm 2012 ; 69:595-597.
3372	Napló	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3433	Napló	Preslaski C.R, Mueller S.W, Wempe M.F, Robert MacLaren R. Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection. Am J Health-Syst Pharm 2013 ; 70:1336-1341
3824	Napló	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	poszter	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poszter	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poszter	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Napló	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4011	Napló	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4029	Napló	Marquis K, Hohlfelder B, Szumita Paul. Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags. Int J Pharm Compound 2017 ; 21, 5: 436-439
4055	Napló	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Napló	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Napló	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4357	Napló	Campos-Baeta, Saavedra-Mitjans M, Garin N, Cardenete J, Cardona D, Riera P. Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition. Nutrition in clinical Practice 2020 ; 35: 967-972.
4389	Napló	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Napló	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Napló	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Napló	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4507	Napló	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Napló	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Napló	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4545	Napló	Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment. Journal of Nippon Medical school 2021
4569	Napló	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4570	Napló	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4603	Napló	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4651	Napló	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Napló	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4723	Napló	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742	Napló	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Napló	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	Napló	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4842	Napló	Souha H Y, Alka G, Yunmei S, Nicole E W, Sanjay G. Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 2024 Drug Design, Development

Mentions Légales